Xenon Pharmaceuticals (XENE)
(Delayed Data from NSDQ)
$41.01 USD
+0.64 (1.59%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $41.02 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Income Statements
Fiscal Year end for Xenon Pharmaceuticals Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 9 | 18 | 32 | 7 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 9 | 18 | 32 | 7 |
Selling & Adminstrative & Depr. & Amort Expenses | 214 | 139 | 97 | 63 | 50 |
Income After Depreciation & Amortization | -214 | -129 | -79 | -31 | -43 |
Non-Operating Income | 31 | 4 | 0 | 3 | 3 |
Interest Expense | 0 | 0 | 0 | 0 | 1 |
Pretax Income | -183 | -125 | -79 | -29 | -42 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -182 | -125 | -79 | -29 | -42 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -182 | -125 | -79 | -29 | -42 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -211 | -128 | -78 | -30 | -42 |
Depreciation & Amortization (Cash Flow) | 4 | 2 | 1 | 1 | 1 |
Income After Depreciation & Amortization | -214 | -129 | -79 | -31 | -43 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 66.89 | 60.54 | 43.63 | 34.54 | 25.94 |
Diluted EPS Before Non-Recurring Items | -2.73 | -2.06 | -1.77 | -0.81 | -1.54 |
Diluted Net EPS (GAAP) | -2.73 | -2.06 | -1.77 | -0.81 | -1.54 |
Fiscal Year end for Xenon Pharmaceuticals Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 59.04 | 53.70 | 55.68 | 55.62 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -59.04 | -53.70 | -55.68 | -55.62 |
Non-Operating Income | NA | 11.52 | 8.75 | 7.07 | 7.94 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -47.52 | -44.95 | -48.62 | -47.68 |
Income Taxes | NA | 0.41 | -0.21 | -0.16 | -0.22 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -47.93 | -44.74 | -48.46 | -47.46 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -47.93 | -44.74 | -48.46 | -47.46 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 77.60 | 69.97 | 66.00 | 65.86 |
Diluted EPS Before Non-Recurring Items | NA | -0.62 | -0.64 | -0.73 | -0.72 |
Diluted Net EPS (GAAP) | NA | -0.62 | -0.65 | -0.73 | -0.72 |